Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
0
Authors
Mark Robson
Mark Robson•Seock‐Ah Im•Pierfranco Conté
Published
June 4, 2017
Abstract
Olaparib is an oral poly(adenosine diphosphate–ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.
